NLRP4 and familial pancreatic carcinoma: The knockdown of NLRP4, the administration of MitoQ, and the use of the autophagy inhibitor CQ all contributed to the enhanced inhibitory effect of olaparib on the proliferation of pancreatic cancer cells (Fig. 7i–l).